BR0212352A - Composição semi-sólida, uso de uma composição de prostaglandina semi-sólida, e, composição de prostaglandina e1 - Google Patents

Composição semi-sólida, uso de uma composição de prostaglandina semi-sólida, e, composição de prostaglandina e1

Info

Publication number
BR0212352A
BR0212352A BR0212352-5A BR0212352A BR0212352A BR 0212352 A BR0212352 A BR 0212352A BR 0212352 A BR0212352 A BR 0212352A BR 0212352 A BR0212352 A BR 0212352A
Authority
BR
Brazil
Prior art keywords
composition
semi
solid
prostaglandin
amino
Prior art date
Application number
BR0212352-5A
Other languages
English (en)
Inventor
James L Yeager
Nadir B Y Ktimkin
Servet B Y Ktimkin
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of BR0212352A publication Critical patent/BR0212352A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO SEMI-SóLIDA, USO DE UMA COMPOSIçãO DE PROSTAGLANDINA SEMI-SóLIDA, E, COMPOSIçãO DE PROSTAGLANDINA E~ 1~". A invenção provê métodos e composições para o tratamento de disfunção erétil. Os métodos incluem a etapa de colocar, dentro da fossa navicularis do paciente, uma quantidade eficaz indutora da ereção de uma composição de prostaglandina vasoativa de uma consistência semi-sólida. A composição compreende uma prostaglandina vasoativa, um melhorador da penetração, um polissacarídeo redutor de cisalhamento, um composto lipofílico, e um sistema de tampão acídico. O melhorador de penetração é um alquil-2-(N-amino substituído)-alcanoato éster, um (N-amino substituído)-alcanol alcanoato, ou uma mistura destes melhoradores. O composto lipofílico pode ser um álcool C~ 1~ a C~ 8~ alifático, um éster C~ 2~ a C~ 30~, ou uma mistura dos mesmos. A composição inclui um sistema tampão provendo um valor de pH tamponado para referida composição na faixa de cerca de 3 a cerca de 7,4.
BR0212352-5A 2001-09-06 2002-09-06 Composição semi-sólida, uso de uma composição de prostaglandina semi-sólida, e, composição de prostaglandina e1 BR0212352A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/947,617 US6693135B2 (en) 2000-01-10 2001-09-06 Prostaglandin compositions and methods of treatment for male erectile dysfunction
PCT/US2002/028507 WO2003022310A1 (en) 2001-09-06 2002-09-06 Prostaglandin compositions and methods of treatment for male erectile dysfunction

Publications (1)

Publication Number Publication Date
BR0212352A true BR0212352A (pt) 2004-07-27

Family

ID=25486427

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212352-5A BR0212352A (pt) 2001-09-06 2002-09-06 Composição semi-sólida, uso de uma composição de prostaglandina semi-sólida, e, composição de prostaglandina e1

Country Status (19)

Country Link
US (1) US6693135B2 (pt)
EP (1) EP1423147B1 (pt)
JP (1) JP4544859B2 (pt)
KR (1) KR20040033024A (pt)
CN (1) CN1551784A (pt)
AT (1) ATE330635T1 (pt)
AU (1) AU2002323650B2 (pt)
BR (1) BR0212352A (pt)
CA (1) CA2457895A1 (pt)
DE (1) DE60212651D1 (pt)
EA (1) EA009384B1 (pt)
GE (1) GEP20063982B (pt)
HU (1) HU229602B1 (pt)
IL (1) IL160404A0 (pt)
MX (1) MXPA04002133A (pt)
NZ (1) NZ531806A (pt)
UA (1) UA79759C2 (pt)
WO (1) WO2003022310A1 (pt)
ZA (1) ZA200401437B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
EA008720B1 (ru) * 1998-12-10 2007-06-29 Нексмед (Холдингс), Инк. Применение композиции на основе простагландина для лечения расстройства сексуального возбуждения у женщин
US20050004226A1 (en) * 1998-12-10 2005-01-06 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US7105571B2 (en) * 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
EP1605913A2 (en) * 2003-03-21 2005-12-21 Nexmed (Holdings), Inc. Angiogenesis promotion by prostaglandin compositions and methods
AU2004224329B2 (en) 2003-03-21 2009-07-09 Nexmed (Holdings), Inc. Compositions and methods for treatment of premature ejaculation
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20060127483A1 (en) * 2004-12-10 2006-06-15 Alan Drizen Topical drug delivery system
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
EP2781505A1 (en) 2006-10-02 2014-09-24 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
AU2006350707A1 (en) 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
CN109503446B (zh) * 2007-01-15 2021-08-20 于崇曦 维生素a酸类和类维生素a酸化合物的前药
WO2008149181A1 (en) 2007-06-04 2008-12-11 Techfields Inc Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
RU2630577C2 (ru) 2008-12-04 2017-09-11 Чунси ЮЙ Композиции интенсивного проникновения и их применение
PL2427475T3 (pl) 2009-05-08 2021-07-19 Techfields Biochem Co., Ltd. Kompozycje proleku o wysokim przenikaniu peptydów i związków powiązanych z peptydami
CA2745320A1 (en) 2011-07-06 2013-01-06 Duoject Medical Systems Inc. Reconstitution device
CN104161720A (zh) * 2014-07-07 2014-11-26 中山尼克美制药有限公司 一种治疗勃起功能障碍的外用前列腺素e1乳膏及制备方法
CN113149982A (zh) 2015-01-20 2021-07-23 Xoc制药股份有限公司 麦角灵化合物及其用途
BR112017015510A2 (pt) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo
JP2020522504A (ja) 2017-06-01 2020-07-30 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ 多環式化合物およびそれらの用途
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
WO2022265537A1 (ru) * 2021-06-18 2022-12-22 Общество с ограниченной ответственностью "ИнертГаз Медикал" Способ лечения эректильной дисфункции

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) 1954-02-11 1958-01-07 Anthony P Miller Surgical device
BE790840A (fr) 1971-11-01 1973-04-30 Upjohn Co Solutions de medicaments instables et leur preparation
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4254145A (en) 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
US4311707A (en) 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
ES2124225T3 (es) 1990-04-25 1999-02-01 Vivus Inc Tratamiento de la disfuncion erectil.
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
JP3202777B2 (ja) 1992-01-24 2001-08-27 リンテック株式会社 経皮吸収促進剤及びテープ製剤
US5380760A (en) 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
CA2215307A1 (en) 1995-03-14 1996-09-19 Vivus, Incorporated Pharmaceutical compositions and kits for preventing erectile dysfunction
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US6046244A (en) 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6224573B1 (en) * 1999-01-15 2001-05-01 Nexmed Holdings, Inc. Medicament dispenser
US6102849A (en) 1999-04-03 2000-08-15 Hakac; John R. Non-surgical penile prosthesis
WO2001035998A1 (en) 1999-11-12 2001-05-25 Pharmaderm Laboratories, Ltd. Compositions for transdermal and transmucosal administration of therapeutic agents
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction

Also Published As

Publication number Publication date
EA200400398A1 (ru) 2004-08-26
JP4544859B2 (ja) 2010-09-15
EP1423147B1 (en) 2006-06-21
JP2005504073A (ja) 2005-02-10
NZ531806A (en) 2006-05-26
HUP0401816A2 (hu) 2004-12-28
WO2003022310A1 (en) 2003-03-20
IL160404A0 (en) 2004-07-25
AU2002323650B2 (en) 2007-12-13
UA79759C2 (en) 2007-07-25
HUP0401816A3 (en) 2012-09-28
DE60212651D1 (de) 2006-08-03
ZA200401437B (en) 2005-05-25
EP1423147A1 (en) 2004-06-02
US20020045665A1 (en) 2002-04-18
ATE330635T1 (de) 2006-07-15
GEP20063982B (en) 2006-12-11
HU229602B1 (en) 2014-02-28
CN1551784A (zh) 2004-12-01
KR20040033024A (ko) 2004-04-17
CA2457895A1 (en) 2003-03-20
MXPA04002133A (es) 2004-06-29
EA009384B1 (ru) 2007-12-28
US6693135B2 (en) 2004-02-17

Similar Documents

Publication Publication Date Title
BR0107478A (pt) Método para tratar a disfunção erétil em um paciente em necessidade de tal tratamento, aplicador, composição de prostaglandina e1, e, uso de uma composição
BR9917299A (pt) Composição tópica e uso de uma composição tópica
BR0109863A (pt) Composições tópicas contendo prostaglandina e1
EA200400398A1 (ru) Композиции простагландина и способы лечения мужской эректильной дисфункции
BRPI0408454A (pt) composição tópica, método de tratar a ejaculação precoce, e, uso da composição
BR9307700A (pt) Formulação para estabilizar uma composição enzimática lìquida, composição enzimática lìquida estabilizada, método para a preparação de uma composição enzimática lìquida estabilizada e método para estabilizar uma composição enzimática lìquida
FI914391A0 (fi) Sammansaettningar vilka foerstaerker hudens permeabilitet.
BR0311877A (pt) Preparações ácidas de insulina com estabilidade aperfeiçoada
DK0782448T3 (da) Ikke-irriterende, ikke-sensibiliserende, ikke-ototoksiske antibakterielle ørepræparater
ES2063073T3 (es) Derivados de arilmetilenilo conocidos y nuevos seleccionados de tiazolidinonas, imidazolidinonas y oxazolidinonas utiles como agentes antialergicos y agentes antiinflamatorios.
PT97441A (pt) Processo para a preparacao de composicoes farmaceuticas que compreendem agentes vasodilatadores, nomeadamente, nitratos, alcaloides ergoticos ou prostaglandinas, ou agentes vasoconstritores, nomeadamente, alcoois benzilicos ou benzenodiois substituidos ou ainda agentes antiflamatorios esteroides e nao esteroides e dispositivos para a sua administracao transuretral
MY101536A (en) Anti-inflammatory and analgesic tape for external use
DK1171100T3 (da) Solubiliseret farmaceutisk komposition til parenteral administration
BR0108455A (pt) Composição cosmética de uma fase, transparente
BR9803730A (pt) Preparados farmacêuticos de cilansetron estabilizados contra a racemização.
DK0981363T3 (da) Somatostatinagonister til reduktion af legemsvægt
TW328049B (en) Penciclover/propylene glycol composition
KR930003925A (ko) 코 및 눈에 국부적으로 사용하기 위한 브래디키닌 길항제 함유 약제학적 조성물
CA2442479A1 (en) Topical compositions for prostaglandin e1 delivery
KR920702623A (ko) 진해제
RU2000101317A (ru) Состав и способ лечения нарушения эректильной дисфункции полового члена
KR970058712A (ko) 새로운 위산분비 억제제를 함유한 주사용 제제
KR20030050044A (ko) 알프로스타딜 알킬 에스테르를 함유하는 외용제 조성물

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 47/10, 47/14, 47/18; A61P 15/00, 43/00

Ipc: A61K 47/10 (2011.01), A61K 47/14 (2011.01), A61K 4

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]